Cardiome Pharma Corp.

Qlt Inc.

Inex Pharmaceuticals Corporation

Her Majesty the Queen in Right of Canada, As Represented by the Minister of Natural Resources, Canadian Forestry Service

Jeffery Jerome Wheeler

Ljiljana Kojic

Pieter Rutter Cullis

Bertrand M C Plouvier

Aregahegn Yifru

Doug Ta Hung Chou

Peter Scherrer

James Gee Ken Yee

Patricia M Logan

Yuan-Peng Zhang

Allen Davidoff

Gabriel Bela Kalmar

Peter Pang

Richard Scott Winder

Kymberley L Sutton

Olga Ludkovski

Edward George Saravolac

This invention is directed to deuterated aminocyclohexyl ether compounds and processes for preparing same and methods of using same.

Deuterated aminocyclohexyl ether compounds and processes for preparing same

Methods are provided to specifically modulate the activation of monocytes and/or macrophages. Administration of integrin linked kinase (ILK) blocking agents; compounds that otherwise prevent the binding of natural ILK ligands to ILK; or compounds that prevent expression of, or signaling through ILK exert an anti-inflammatory effect by inhibiting iNOS and COX-2 expression, at the level of transcription by suppressing the activation of NF-&#x3ba;B. The modulation of activation through ILK is used to regulate immune processes at targeted sites, for example to decrease undesirable inflammatory responses.

Integrin linked kinase modulation of monocyte activation

The present invention relates to lipid-based formulations for nucleic acid delivery to cells, methods for the preparation of such formulations and, in particular, to lipid encapsulated plasmids. The compositions are safe and practical for clinical use. In addition, the present invention provides methods for introducing nucleic acids into cells and for inhibiting tumor growth in cells using such lipid-nucleic acid formulations.

Methods for encapsulating nucleic acids in lipid bilayers

Microparticles such as propagules of eukaryotic biocontrol agents are encapsulated in cellular-scale polymer capsules that have a diameter similar to normal eukaryotic cells in a range of about 10 &mgr;m to about 400 &mgr;m. The microparticles are encapsulated by adding a hydrophobic dispersion medium such as a mixture of chloroform and hexane or a mixture of corn oil and n-hexadecane having a specific gravity of about 1 and containing an emulsifier such as lecithin to an aqueous suspension of the microparticles and a polymer matrix precursor such as alginate, agitating vigorously to form a stable emulsion of microscopic globules containing a microparticle, and adding the emulsion to an aqueous solution containing a polymerizing agent such as calcium chloride to polymerize and precipitate the globules to form microparticles encapsulated in polymer matrix capsules that may be of a teardrop shape having a length of 40-200% longer than the diameter. Precipitation of the globules is regulated by substantially matching the Specific Gravity of the hydrophobic dispersion medium and the aqueous suspension. The microparticle may be a viable propagule of a weed pathogenic fungus to provide a herbicidal composition.

Encapsulation of microparticles in teardrop shaped polymer capsules of cellular size

Growing community of inventors

Surrey, Canada

Jeffery Jerome Wheeler